1. Home
  2. MC vs ACAD Comparison

MC vs ACAD Comparison

Compare MC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moelis & Company

MC

Moelis & Company

SELL

Current Price

$54.55

Market Cap

4.2B

Sector

Finance

ML Signal

SELL

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$18.97

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MC
ACAD
Founded
2007
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.4B
IPO Year
2014
2000

Fundamental Metrics

Financial Performance
Metric
MC
ACAD
Price
$54.55
$18.97
Analyst Decision
Hold
Buy
Analyst Count
11
20
Target Price
★ $67.50
$30.53
AVG Volume (30 Days)
917.1K
★ 2.3M
Earning Date
11-05-2026
11-04-2026
Dividend Yield
★ 4.70%
N/A
EPS Growth
N/A
★ 69.12
EPS
★ 0.75
0.20
Revenue
N/A
★ $726,437,000.00
Revenue This Year
$14.07
$18.71
Revenue Next Year
$17.57
$12.44
P/E Ratio
★ $73.77
$98.53
Revenue Growth
N/A
★ 40.45
52 Week Low
$51.06
$18.39
52 Week High
$78.22
$30.96

Technical Indicators

Market Signals
Indicator
MC
ACAD
Relative Strength Index (RSI) 32.07 26.82
Support Level $51.06 N/A
Resistance Level $56.79 $22.92
Average True Range (ATR) 1.77 0.57
MACD 0.09 0.11
Stochastic Oscillator 20.70 36.57

Price Performance

Historical Comparison
MC
ACAD

About MC Moelis & Company

Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. It generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States, followed by Europe and the rest of the World.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: